TDP43 promotes stemness of breast cancer stem cells through CD44 variant splicing isoforms

Abstract Alternative splicing (AS) is a promising clinical target for cancer treatment at the post-transcriptional level. We previously identified a unique AS profile in triple-negative breast cancer (TNBC), which is regulated by the splicing regulator TAR DNA-binding protein-43 (TDP43), thus indica...

Full description

Bibliographic Details
Main Authors: Lu Guo, Hao Ke, Honglei Zhang, Li Zou, Qin Yang, Xuemei Lu, Limin Zhao, Baowei Jiao
Format: Article
Language:English
Published: Nature Publishing Group 2022-05-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-022-04867-w